BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006;354:709-718. [PMID: 16481638 DOI: 10.1056/NEJMoa053007] [Cited by in Crossref: 478] [Cited by in F6Publishing: 410] [Article Influence: 29.9] [Reference Citation Analysis]
Number Citing Articles
1 Rodgers CB, Mustard CJ, McLean RT, Hutchison S, Pritchard AL. A B-cell or a key player? The different roles of B-cells and antibodies in melanoma. Pigment Cell Melanoma Res 2022;35:303-19. [PMID: 35218154 DOI: 10.1111/pcmr.13031] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Park BC, Stone CA, Dewan AK, Johnson DB. Hypersensitivity Reactions and Immune-Related Adverse Events to Immune Checkpoint Inhibitors: Approaches, Mechanisms, and Models. Immunology and Allergy Clinics of North America 2022. [DOI: 10.1016/j.iac.2021.12.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Makunda N, Vallabhaneni S, Lefebvre B, Fradley MG. Cardiotoxicity of Systemic Melanoma Treatments. Curr Treat Options Oncol 2022. [PMID: 35192138 DOI: 10.1007/s11864-021-00924-2] [Reference Citation Analysis]
4 Scatozza F, Facchiano A. Expression of Autoimmunity-Related Genes in Melanoma. Cancers 2022;14:991. [DOI: 10.3390/cancers14040991] [Reference Citation Analysis]
5 Harada M, Kimura F, Takai Y, Nakajima T, Ushijima K, Kobayashi H, Satoh T, Tozawa A, Sugimoto K, Saji S, Shimizu C, Akiyama K, Bando H, Kuwahara A, Furui T, Okada H, Kawai K, Shinohara N, Nagao K, Kitajima M, Suenobu S, Soejima T, Miyachi M, Miyoshi Y, Yoneda A, Horie A, Ishida Y, Usui N, Kanda Y, Fujii N, Endo M, Nakayama R, Hoshi M, Yonemoto T, Kiyotani C, Okita N, Baba E, Muto M, Kikuchi I, Morishige KI, Tsugawa K, Nishiyama H, Hosoi H, Tanimoto M, Kawai A, Sugiyama K, Boku N, Yonemura M, Hayashi N, Aoki D, Osuga Y, Suzuki N. Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adult cancer patients: part 1. Int J Clin Oncol 2022. [PMID: 34973107 DOI: 10.1007/s10147-021-02081-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Bastacky ML, Wang H, Fortman D, Rahman Z, Mascara GP, Brenner T, Najjar YG, Luke JJ, Kirkwood JM, Zarour HM, Davar D. Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis. Front Oncol 2021;11:749064. [PMID: 34900695 DOI: 10.3389/fonc.2021.749064] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
7 Gulati N, Celen A, Johannet P, Mehnert JM, Weber J, Krogsgaard M, Osman I, Zhong J. Preexisting immune-mediated inflammatory disease is associated with improved survival and increased toxicity in melanoma patients who receive immune checkpoint inhibitors. Cancer Med 2021;10:7457-65. [PMID: 34647433 DOI: 10.1002/cam4.4239] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Peterson P, Kisand K, Kluger N, Ranki A. Loss of AIRE-Mediated Immune Tolerance and the Skin. J Invest Dermatol 2021:S0022-202X(21)01241-0. [PMID: 34535292 DOI: 10.1016/j.jid.2021.04.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Meng X, Lei Y, Zhang X, Sun K, Zhang L, Wang Z. Cancer immunotherapy: Classification, therapeutic mechanisms, and nanomaterial-based synergistic therapy. Applied Materials Today 2021;24:101149. [DOI: 10.1016/j.apmt.2021.101149] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Brammer JE, Braunstein Z, Katapadi A, Porter K, Biersmith M, Guha A, Vasu S, Yildiz VO, Smith SA, Buck B, Haddad D, Gumina R, William BM, Penza S, Saad A, Denlinger N, Vallakati A, Baliga R, Benza R, Binkley P, Wei L, Mocarski M, Devine SM, Jaglowski S, Addison D. Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma. J Immunother Cancer 2021;9:e002303. [PMID: 34429331 DOI: 10.1136/jitc-2020-002303] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
11 Yang SH, Liu CT, Hong CQ, Huang ZY, Wang HZ, Wei LF, Lin YW, Guo HP, Peng YH, Xu YW. Autoantibodies against p53, MMP-7, and Hsp70 as Potential Biomarkers for Detection of Nonmelanoma Skin Cancers. Dis Markers 2021;2021:5592693. [PMID: 34336006 DOI: 10.1155/2021/5592693] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Hoteit M, Oneissi Z, Reda R, Wakim F, Zaidan A, Farran M, Abi-Khalil E, El-Sibai M. Cancer immunotherapy: A comprehensive appraisal of its modes of application. Oncol Lett 2021;22:655. [PMID: 34386077 DOI: 10.3892/ol.2021.12916] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
13 Kaur D, Arora C, Raghava GPS. Prognostic Biomarker-Based Identification of Drugs for Managing the Treatment of Endometrial Cancer. Mol Diagn Ther 2021;25:629-46. [PMID: 34155607 DOI: 10.1007/s40291-021-00539-1] [Reference Citation Analysis]
14 Les I, Martínez M, Narro A, Pérez I, Sánchez C, Puntí L, Anaut P, Eguiluz S, Herrera A, Domínguez S. Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies. Ann Med 2021;53:762-9. [PMID: 34060971 DOI: 10.1080/07853890.2021.1931956] [Reference Citation Analysis]
15 Tarhini AA, Kang N, Lee SJ, Hodi FS, Cohen GI, Hamid O, Hutchins LF, Sosman JA, Kluger HM, Eroglu Z, Koon HB, Lawrence DP, Kendra KL, Minor DR, Lee CB, Albertini MR, Flaherty LE, Petrella TM, Streicher H, Sondak VK, Kirkwood JM. Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis. J Immunother Cancer 2021;9:e002535. [PMID: 33963015 DOI: 10.1136/jitc-2021-002535] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
16 Wang R, Zhao H, Liu Y, Kang B, Cai J. Antinuclear Antibodies With a Nucleolar Pattern Are Associated With a Significant Reduction in the Overall Survival of Patients With Leukemia: A Retrospective Cohort Study. Front Oncol 2021;11:631038. [PMID: 33718211 DOI: 10.3389/fonc.2021.631038] [Reference Citation Analysis]
17 Wang E, Uccellini L, Marincola FM. A genetic inference on cancer immune responsiveness. Oncoimmunology 2012;1:520-5. [PMID: 22754772 DOI: 10.4161/onci.19531] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 30.0] [Reference Citation Analysis]
18 Katewa A, Suto E, Hui J, Heredia J, Liang J, Hackney J, Anderson K, Alcantar TM, Bacarro N, Dunlap D, Eastham J, Paler-Martinez A, Rairdan XY, Modrusan Z, Lee WP, Austin CD, Lafkas D, Ghilardi N. The peptide symporter SLC15a4 is essential for the development of systemic lupus erythematosus in murine models. PLoS One 2021;16:e0244439. [PMID: 33444326 DOI: 10.1371/journal.pone.0244439] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
19 Eggermont AMM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Krepler C, Ibrahim N, Marreaud S, van Akkooi A, Robert C, Suciu S. Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol 2020;6:519-27. [PMID: 31895407 DOI: 10.1001/jamaoncol.2019.5570] [Cited by in Crossref: 100] [Cited by in F6Publishing: 145] [Article Influence: 50.0] [Reference Citation Analysis]
20 Willemsen M, Melief CJM, Bekkenk MW, Luiten RM. Targeting the PD-1/PD-L1 Axis in Human Vitiligo. Front Immunol 2020;11:579022. [PMID: 33240267 DOI: 10.3389/fimmu.2020.579022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
21 Momin N, Mehta NK, Bennett NR, Ma L, Palmeri JR, Chinn MM, Lutz EA, Kang B, Irvine DJ, Spranger S, Wittrup KD. Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy. Sci Transl Med 2019;11:eaaw2614. [PMID: 31243150 DOI: 10.1126/scitranslmed.aaw2614] [Cited by in Crossref: 54] [Cited by in F6Publishing: 76] [Article Influence: 27.0] [Reference Citation Analysis]
22 Brugnara S, Sicher M, Bonandini EM, Barbareschi M, Girardelli CR, Caffo O. Onset of vitiligo following targeted therapy for BRAFV600E-mutated melanoma: case report. Drugs Context 2019;8:212582. [PMID: 32158480 DOI: 10.7573/dic.212582] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Bai X, Fisher DE, Flaherty KT. Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways. Nat Rev Clin Oncol 2019;16:549-62. [PMID: 30967646 DOI: 10.1038/s41571-019-0204-6] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 14.3] [Reference Citation Analysis]
24 Presotto EM, Rastrelli G, Desideri I, Scotti V, Gunnella S, Pimpinelli N, Vaccher E, Bearz A, Di Costanzo F, Bruggia M, Mini E, Maggi M, Peri A. Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study. J Endocrinol Invest 2020;43:337-45. [PMID: 31542865 DOI: 10.1007/s40618-019-01112-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
25 Khan S, Gerber DE. Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review. Semin Cancer Biol 2020;64:93-101. [PMID: 31330185 DOI: 10.1016/j.semcancer.2019.06.012] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 12.0] [Reference Citation Analysis]
26 Willemsen M, Linkutė R, Luiten RM, Matos TR. Skin-resident memory T cells as a potential new therapeutic target in vitiligo and melanoma. Pigment Cell Melanoma Res 2019;32:612-22. [PMID: 31230406 DOI: 10.1111/pcmr.12803] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
27 Maurer DM, Butterfield LH, Vujanovic L. Melanoma vaccines: clinical status and immune endpoints. Melanoma Res 2019;29:109-18. [PMID: 30802228 DOI: 10.1097/CMR.0000000000000535] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
28 Butterfield LH, Vujanovic L, Santos PM, Maurer DM, Gambotto A, Lohr J, Li C, Waldman J, Chandran U, Lin Y, Lin H, Tawbi HA, Tarhini AA, Kirkwood JM. Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma. J Immunother Cancer 2019;7:113. [PMID: 31014399 DOI: 10.1186/s40425-019-0552-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
29 Margolis N, Markovits E, Markel G. Reprogramming lymphocytes for the treatment of melanoma: From biology to therapy. Adv Drug Deliv Rev 2019;141:104-24. [PMID: 31276707 DOI: 10.1016/j.addr.2019.06.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
30 Vujanovic L, Chuckran C, Lin Y, Ding F, Sander CA, Santos PM, Lohr J, Mashadi-Hossein A, Warren S, White A, Huang A, Kirkwood JM, Butterfield LH. CD56dim CD16- Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon-α. Front Immunol 2019;10:14. [PMID: 30761123 DOI: 10.3389/fimmu.2019.00014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
31 Imam S, Dar P, Paparodis R, Almotah K, Al-Khudhair A, Hasan SA, Salim N, Jaume JC. Nature of coexisting thyroid autoimmune disease determines success or failure of tumor immunity in thyroid cancer. J Immunother Cancer 2019;7:3. [PMID: 30616690 DOI: 10.1186/s40425-018-0483-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
32 Bridge JA, Lee JC, Daud A, Wells JW, Bluestone JA. Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer. Front Med (Lausanne) 2018;5:351. [PMID: 30631766 DOI: 10.3389/fmed.2018.00351] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 7.8] [Reference Citation Analysis]
33 Indini A, Di Guardo L, Cimminiello C, Prisciandaro M, Randon G, De Braud F, Del Vecchio M. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. J Cancer Res Clin Oncol 2019;145:511-21. [PMID: 30539281 DOI: 10.1007/s00432-018-2819-x] [Cited by in Crossref: 94] [Cited by in F6Publishing: 107] [Article Influence: 23.5] [Reference Citation Analysis]
34 Douguet L, Bod L, Labarthe L, Lengagne R, Kato M, Couillin I, Prévost-Blondel A. Inflammation drives nitric oxide synthase 2 expression by γδ T cells and affects the balance between melanoma and vitiligo associated melanoma. Oncoimmunology 2018;7:e1484979. [PMID: 30228955 DOI: 10.1080/2162402X.2018.1484979] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
35 Francisco G, Rao BK, Victor FC. Two reports of malignant melanoma arising within a new vitiligo-like depigmented patch. JAAD Case Rep 2018;4:573-5. [PMID: 29998177 DOI: 10.1016/j.jdcr.2018.05.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
36 Ali Khan W. Recombinant interferon alpha 2b in rheumatoid arthritis: good antigen for rheumatoid arthritis antibodies. Cent Eur J Immunol 2018;43:58-68. [PMID: 29736147 DOI: 10.5114/ceji.2018.74874] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
37 Costa R, Carneiro BA, Agulnik M, Rademaker AW, Pai SG, Villaflor VM, Cristofanilli M, Sosman JA, Giles FJ. Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. Oncotarget 2017;8:8910-20. [PMID: 27852042 DOI: 10.18632/oncotarget.13315] [Cited by in Crossref: 80] [Cited by in F6Publishing: 80] [Article Influence: 20.0] [Reference Citation Analysis]
38 Osorio JC, Ni A, Chaft JE, Pollina R, Kasler MK, Stephens D, Rodriguez C, Cambridge L, Rizvi H, Wolchok JD, Merghoub T, Rudin CM, Fish S, Hellmann MD. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol. 2017;28:583-589. [PMID: 27998967 DOI: 10.1093/annonc/mdw640] [Cited by in Crossref: 263] [Cited by in F6Publishing: 324] [Article Influence: 52.6] [Reference Citation Analysis]
39 Guaraldi F, La Selva R, Samà MT, D'Angelo V, Gori D, Fava P, Fierro MT, Savoia P, Arvat E. Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution. J Endocrinol Invest 2018;41:549-56. [PMID: 29043574 DOI: 10.1007/s40618-017-0772-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
40 Dinse GE, Parks CG, Weinberg CR, Meier HCS, Co CA, Chan EKL, Miller FW. Antinuclear antibodies and mortality in the National Health and Nutrition Examination Survey (1999-2004). PLoS One 2017;12:e0185977. [PMID: 29016697 DOI: 10.1371/journal.pone.0185977] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
41 Bakhru P, Zhu ML, Wang HH, Hong LK, Khan I, Mouchess M, Gulati AS, Starmer J, Hou Y, Sailer D, Lee S, Zhao F, Kirkwood JM, Moschos S, Fong L, Anderson MS, Su MA. Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity. JCI Insight 2017;2:93265. [PMID: 28931755 DOI: 10.1172/jci.insight.93265] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
42 Byrne EH, Fisher DE. Immune and molecular correlates in melanoma treated with immune checkpoint blockade. Cancer. 2017;123:2143-2153. [PMID: 28543699 DOI: 10.1002/cncr.30444] [Cited by in Crossref: 64] [Cited by in F6Publishing: 72] [Article Influence: 12.8] [Reference Citation Analysis]
43 Margolin K. The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma. Curr Treat Options Oncol 2016;17:48. [PMID: 27461037 DOI: 10.1007/s11864-016-0421-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
44 Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, Hakansson LG, Hanks BA, Karanikas V, Khleif SN, Kirkwood JM, Miller LD, Schendel DJ, Tanneau I, Wigginton JM, Butterfield LH. Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J Immunother Cancer 2017;5:44. [PMID: 28515944 DOI: 10.1186/s40425-017-0243-4] [Cited by in Crossref: 115] [Cited by in F6Publishing: 130] [Article Influence: 23.0] [Reference Citation Analysis]
45 Brohl AS, Khushalani NI, Eroglu Z, Markowitz J, Thapa R, Chen YA, Kudchadkar R, Weber JS. A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma. J Immunother Cancer. 2016;4:85. [PMID: 28031816 DOI: 10.1186/s40425-016-0194-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
46 Menon S, Shin S, Dy G. Advances in Cancer Immunotherapy in Solid Tumors. Cancers (Basel) 2016;8:E106. [PMID: 27886124 DOI: 10.3390/cancers8120106] [Cited by in Crossref: 88] [Cited by in F6Publishing: 92] [Article Influence: 14.7] [Reference Citation Analysis]
47 Cappelli LC, Shah AA, Bingham CO 3rd. Immune-Related Adverse Effects of Cancer Immunotherapy- Implications for Rheumatology. Rheum Dis Clin North Am 2017;43:65-78. [PMID: 27890174 DOI: 10.1016/j.rdc.2016.09.007] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 11.5] [Reference Citation Analysis]
48 Xin Y, Huang Q, Zhang P, Yang M, Hou XY, Tang JQ, Zhang LZ, Jiang G. Meta-Analysis of the Safety and Efficacy of Interferon Combined With Dacarbazine Versus Dacarbazine Alone in Cutaneous Malignant Melanoma. Medicine (Baltimore) 2016;95:e3406. [PMID: 27100429 DOI: 10.1097/MD.0000000000003406] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
49 Navid F, Herzog CE, Sandoval J, Daryani VM, Stewart CF, Gattuso J, Mandrell B, Phipps S, Chemaitilly W, Sykes A, Davidoff AM, Shulkin BL, Bahrami A, Furman WL, Mao S, Wu J, Schiff D, Rao B, Pappo A. Feasibility of Pegylated Interferon in Children and Young Adults With Resected High-Risk Melanoma. Pediatr Blood Cancer 2016;63:1207-13. [PMID: 27038395 DOI: 10.1002/pbc.25983] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
50 Tan AC, Goubier A, Kohrt HE. A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial. J Immunother Cancer 2015;3:48. [PMID: 26579225 DOI: 10.1186/s40425-015-0093-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
51 Vogelsang M, Wilson M, Kirchhoff T. Germline determinants of clinical outcome of cutaneous melanoma. Pigment Cell Melanoma Res 2016;29:15-26. [PMID: 26342156 DOI: 10.1111/pcmr.12418] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
52 Munhoz RR, González AF, Reed VA, Postow MA. Targeting immune checkpoints in melanoma: an update. Melanoma Manag 2015;2:339-52. [PMID: 30190862 DOI: 10.2217/mmt.15.25] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
53 Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. Clin Cancer Res. 2016;22:886-894. [PMID: 26446948 DOI: 10.1158/1078-0432.ccr-15-1136] [Cited by in Crossref: 443] [Cited by in F6Publishing: 485] [Article Influence: 63.3] [Reference Citation Analysis]
54 Mangana J, Cheng PF, Schindler K, Weide B, Held U, Frauchiger AL, Romano E, Kähler KC, Rozati S, Rechsteiner M, Moch H, Michielin O, Garbe C, Hauschild A, Hoeller C, Dummer R, Goldinger SM. Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival? PLoS One 2015;10:e0139438. [PMID: 26426340 DOI: 10.1371/journal.pone.0139438] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
55 Linsley PS, Chaussabel D, Speake C. The Relationship of Immune Cell Signatures to Patient Survival Varies within and between Tumor Types. PLoS One 2015;10:e0138726. [PMID: 26398410 DOI: 10.1371/journal.pone.0138726] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
56 Koirala R, Gyorki D. Targeting the Immune System for Cancer Therapy: Lessons for Perioperative Management? Curr Anesthesiol Rep 2015;5:257-67. [DOI: 10.1007/s40140-015-0111-z] [Reference Citation Analysis]
57 Baldo BA. Side effects of cytokines approved for therapy. Drug Saf 2014;37:921-43. [PMID: 25270293 DOI: 10.1007/s40264-014-0226-z] [Cited by in Crossref: 75] [Cited by in F6Publishing: 77] [Article Influence: 10.7] [Reference Citation Analysis]
58 Rochet NM, Kottschade LA, Grotz TE, Porrata LF, Markovic SN. The prognostic role of the preoperative absolute lymphocyte count and absolute monocyte count in patients with resected advanced melanoma. Am J Clin Oncol 2015;38:252-8. [PMID: 23774073 DOI: 10.1097/COC.0b013e31829b5605] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
59 Tarhini AA, Lin Y, Zahoor H, Shuai Y, Butterfield LH, Ringquist S, Gogas H, Sander C, Lee S, Agarwala SS, Kirwood JM. Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients. PLoS One 2015;10:e0132745. [PMID: 26192408 DOI: 10.1371/journal.pone.0132745] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
60 Floros T, Tarhini AA. Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12. Semin Oncol 2015;42:539-48. [PMID: 26320059 DOI: 10.1053/j.seminoncol.2015.05.015] [Cited by in Crossref: 100] [Cited by in F6Publishing: 111] [Article Influence: 14.3] [Reference Citation Analysis]
61 Paul F, Pellegrini S, Uzé G. IFNA2: The prototypic human alpha interferon. Gene 2015;567:132-7. [PMID: 25982860 DOI: 10.1016/j.gene.2015.04.087] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
62 Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of Immunotherapy for the Practitioner. J Clin Oncol. 2015;33:2092-2099. [PMID: 25918278 DOI: 10.1200/jco.2014.60.0379] [Cited by in Crossref: 374] [Cited by in F6Publishing: 384] [Article Influence: 53.4] [Reference Citation Analysis]
63 Butterfield LH. Cancer vaccines. BMJ 2015;350:h988. [PMID: 25904595 DOI: 10.1136/bmj.h988] [Cited by in Crossref: 124] [Cited by in F6Publishing: 125] [Article Influence: 17.7] [Reference Citation Analysis]
64 Shah AA, Casciola-Rosen L, Rosen A. Review: cancer-induced autoimmunity in the rheumatic diseases. Arthritis Rheumatol 2015;67:317-26. [PMID: 25371098 DOI: 10.1002/art.38928] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 7.4] [Reference Citation Analysis]
65 Karagöz B, Bilgi O, Özgün A, Emirzeoğlu L, Çelik S, Özet A. Long term survival with the combination of interferon and chemotherapy in metastatic melanoma. J Egypt Natl Canc Inst 2015;27:161-3. [PMID: 25773731 DOI: 10.1016/j.jnci.2015.02.004] [Reference Citation Analysis]
66 Reusser NM, Downing C, Guidry J, Tyring SK. HPV Carcinomas in Immunocompromised Patients. J Clin Med. 2015;4:260-281. [PMID: 26239127 DOI: 10.3390/jcm4020260] [Cited by in Crossref: 72] [Cited by in F6Publishing: 57] [Article Influence: 10.3] [Reference Citation Analysis]
67 Schrama D, Ugurel S, Sucker A, Ritter C, Zapatka M, Schadendorf D, Becker JC. STAT3 Single Nucleotide Polymorphism rs4796793 SNP Does Not Correlate with Response to Adjuvant IFNα Therapy in Stage III Melanoma Patients. Front Med (Lausanne) 2014;1:47. [PMID: 25593920 DOI: 10.3389/fmed.2014.00047] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
68 Tarhini AA, Shin D, Lee SJ, Stuckert J, Sander CA, Kirkwood JM. Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa. Melanoma Res 2014;24:150-7. [PMID: 24509407 DOI: 10.1097/CMR.0000000000000050] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
69 Antonelli G, Scagnolari C, Moschella F, Proietti E. Twenty-five years of type I interferon-based treatment: a critical analysis of its therapeutic use. Cytokine Growth Factor Rev 2015;26:121-31. [PMID: 25578520 DOI: 10.1016/j.cytogfr.2014.12.006] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
70 Linsley PS, Speake C, Whalen E, Chaussabel D. Copy number loss of the interferon gene cluster in melanomas is linked to reduced T cell infiltrate and poor patient prognosis. PLoS One 2014;9:e109760. [PMID: 25314013 DOI: 10.1371/journal.pone.0109760] [Cited by in Crossref: 107] [Cited by in F6Publishing: 94] [Article Influence: 13.4] [Reference Citation Analysis]
71 Srivastava N, McDermott D. Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape. Cancer Manag Res 2014;6:279-89. [PMID: 25018651 DOI: 10.2147/CMAR.S64979] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
72 Tang HC, Chen CY. Drug design of cyclin-dependent kinase 2 inhibitor for melanoma from traditional Chinese medicine. Biomed Res Int 2014;2014:798742. [PMID: 25045703 DOI: 10.1155/2014/798742] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
73 Shevtsov MA, Kim AV, Samochernych KA, Romanova IV, Margulis BA, Guzhova IV, Yakovenko IV, Ischenko AM, Khachatryan WA. Pilot study of intratumoral injection of recombinant heat shock protein 70 in the treatment of malignant brain tumors in children. Onco Targets Ther 2014;7:1071-81. [PMID: 24971017 DOI: 10.2147/OTT.S62764] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
74 De Remigis A, de Gruijl TD, Uram JN, Tzou SC, Iwama S, Talor MV, Armstrong TD, Santegoets SJ, Slovin SF, Zheng L. Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival. Int J Cancer. 2015;136:127-137. [PMID: 24832153 DOI: 10.1002/ijc.28973] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
75 Imam S, Paparodis R, Sharma D, Jaume JC. Lymphocytic profiling in thyroid cancer provides clues for failure of tumor immunity. Endocr Relat Cancer 2014;21:505-16. [PMID: 24623740 DOI: 10.1530/ERC-13-0436] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
76 Hendry DJ. Data generation for the Cox proportional hazards model with time-dependent covariates: a method for medical researchers. Stat Med 2014;33:436-54. [PMID: 24014094 DOI: 10.1002/sim.5945] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
77 Kottke T, Boisgerault N, Diaz RM, Donnelly O, Rommelfanger-Konkol D, Pulido J, Thompson J, Mukhopadhyay D, Kaspar R, Coffey M, Pandha H, Melcher A, Harrington K, Selby P, Vile R. Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence. Nat Med 2013;19:1625-31. [PMID: 24240185 DOI: 10.1038/nm.3397] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
78 Naveh HP, Rao UN, Butterfield LH. Melanoma-associated leukoderma - immunology in black and white? Pigment Cell Melanoma Res 2013;26:796-804. [PMID: 24010963 DOI: 10.1111/pcmr.12161] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
79 Gyorki DE, Callahan M, Wolchok JD, Ariyan CE. The delicate balance of melanoma immunotherapy. Clin Transl Immunology 2013;2:e5. [PMID: 25505953 DOI: 10.1038/cti.2013.5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
80 Boisgerault N, Kottke T, Pulido J, Thompson J, Diaz RM, Rommelfanger-Konkol D, Embry A, Saenz D, Poeschla E, Pandha H, Harrington K, Melcher A, Selby P, Vile R. Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse. Mol Ther 2013;21:1507-16. [PMID: 23752316 DOI: 10.1038/mt.2013.116] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
81 Ascierto PA, Grimaldi AM, Acquavella N, Borgognoni L, Calabrò L, Cascinelli N, Cesano A, Del Vecchio M, Eggermont AM, Faries M, Ferrone S, Fox BA, Gajewski TF, Galon J, Gnjatic S, Gogas H, Kashani-Sabet M, Kaufman HL, Larkin J, Lo RS, Mantovani A, Margolin K, Melief C, McArthur G, Palmieri G, Puzanov I, Ribas A, Seliger B, Sosman J, Suenaert P, Tarhini AA, Trinchieri G, Vidal-Vanaclocha F, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". J Transl Med 2013;11:137. [PMID: 23731854 DOI: 10.1186/1479-5876-11-137] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
82 Tarhini A. Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo). 2013;2013:857519. [PMID: 24278787 DOI: 10.1155/2013/857519] [Cited by in Crossref: 82] [Cited by in F6Publishing: 111] [Article Influence: 9.1] [Reference Citation Analysis]
83 Schlegel J, Sambade MJ, Sather S, Moschos SJ, Tan AC, Winges A, DeRyckere D, Carson CC, Trembath DG, Tentler JJ, Eckhardt SG, Kuan PF, Hamilton RL, Duncan LM, Miller CR, Nikolaishvili-Feinberg N, Midkiff BR, Liu J, Zhang W, Yang C, Wang X, Frye SV, Earp HS, Shields JM, Graham DK. MERTK receptor tyrosine kinase is a therapeutic target in melanoma. J Clin Invest 2013;123:2257-67. [PMID: 23585477 DOI: 10.1172/JCI67816] [Cited by in Crossref: 95] [Cited by in F6Publishing: 97] [Article Influence: 10.6] [Reference Citation Analysis]
84 Tarhini AA, Butterfield LH, Shuai Y, Gooding WE, Kalinski P, Kirkwood JM. Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination. J Immunother 2012;35:702-10. [PMID: 23090079 DOI: 10.1097/CJI.0b013e318272569b] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 5.2] [Reference Citation Analysis]
85 Körner R, Preuss KD, Fadle N, Madjidi D, Neumann F, Bergeler L, Gräber S, Müller CS, Grünhage F, Pfreundschuh M, Lammert F, Vogt T, Pföhler C. Serum antibodies against CD28-- a new potential marker of dismal prognosis in melanoma patients. PLoS One 2013;8:e58087. [PMID: 23483974 DOI: 10.1371/journal.pone.0058087] [Reference Citation Analysis]
86 Garcin G, Bordat Y, Chuchana P, Monneron D, Law HK, Piehler J, Uzé G. Differential activity of type I interferon subtypes for dendritic cell differentiation. PLoS One 2013;8:e58465. [PMID: 23472200 DOI: 10.1371/journal.pone.0058465] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
87 Daponte A, Signoriello S, Maiorino L, Massidda B, Simeone E, Grimaldi AM, Caracò C, Palmieri G, Cossu A, Botti G, Petrillo A, Lastoria S, Cavalcanti E, Aprea P, Mozzillo N, Gallo C, Comella G, Ascierto PA; Southern Italy Cooperative Oncology Group (SICOG). Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma. J Transl Med 2013;11:38. [PMID: 23402397 DOI: 10.1186/1479-5876-11-38] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
88 Zhu ML, Nagavalli A, Su MA. Aire deficiency promotes TRP-1-specific immune rejection of melanoma. Cancer Res 2013;73:2104-16. [PMID: 23370329 DOI: 10.1158/0008-5472.CAN-12-3781] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 3.9] [Reference Citation Analysis]
89 Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, Bergmann T, Bockmeyer CL, Eigentler T, Fluck M, Garbe C, Gutzmer R, Grabbe S, Hauschild A, Hein R, Hundorfean G, Justich A, Keller U, Klein C, Mateus C, Mohr P, Paetzold S, Satzger I, Schadendorf D, Schlaeppi M, Schuler G, Schuler-Thurner B, Trefzer U, Ulrich J, Vaubel J, von Moos R, Weder P, Wilhelm T, Göppner D, Dummer R, Heinzerling LM. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One 2013;8:e53745. [PMID: 23341990 DOI: 10.1371/journal.pone.0053745] [Cited by in Crossref: 319] [Cited by in F6Publishing: 315] [Article Influence: 35.4] [Reference Citation Analysis]
90 Lenci RE, Bevier M, Brandt A, Bermejo JL, Sucker A, Moll I, Planelles D, Requena C, Nagore E, Hemminki K, Schadendorf D, Kumar R. Influence of genetic variants in type I interferon genes on melanoma survival and therapy. PLoS One 2012;7:e50692. [PMID: 23209811 DOI: 10.1371/journal.pone.0050692] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
91 Zhang JB, Sun HC, Jia WD, Zhuang PY, Qian YB, Zhu XD, Kong LQ, Wang L, Wu WZ, Tang ZY. Up-regulation of platelet-derived growth factor-A is responsible for the failure of re-initiated interferon alpha treatment in hepatocellular carcinoma. BMC Cancer 2012;12:439. [PMID: 23025904 DOI: 10.1186/1471-2407-12-439] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
92 Uccellini L, De Giorgi V, Zhao Y, Tumaini B, Erdenebileg N, Dudley ME, Tomei S, Bedognetti D, Ascierto ML, Liu Q, Simon R, Kottyan L, Kaufman KM, Harley JB, Wang E, Rosenberg SA, Marincola FM. IRF5 gene polymorphisms in melanoma. J Transl Med 2012;10:170. [PMID: 22909381 DOI: 10.1186/1479-5876-10-170] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
93 Leong SP, Mihm MC, Murphy GF, Hoon DS, Kashani-Sabet M, Agarwala SS, Zager JS, Hauschild A, Sondak VK, Guild V. Progression of cutaneous melanoma: implications for treatment. Clin Exp Metastasis. 2012;29:775-796. [PMID: 22892755 DOI: 10.1007/s10585-012-9521-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
94 Tarhini AA, Leng S, Moschos SJ, Yin Y, Sander C, Lin Y, Gooding WE, Kirkwood JM. Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. J Immunother. 2012;35:359-366. [PMID: 22495394 DOI: 10.1097/cji.0b013e31825481fe] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 4.1] [Reference Citation Analysis]
95 Davar D, Tarhini AA, Kirkwood JM. Adjuvant therapy for melanoma. Cancer J 2012;18:192-202. [PMID: 22453021 DOI: 10.1097/PPO.0b013e31824f118b] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
96 Márquez-Rodas I, Martín Algarra S, Avilés Izquierdo JA, Custodio Cabello S, Martín M. A new era in the treatment of melanoma: from biology to clinical practice. Clin Transl Oncol 2011;13:787-92. [PMID: 22082642 DOI: 10.1007/s12094-011-0734-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
97 Ascierto PA, Grimaldi AM, Curti B, Faries MB, Ferrone S, Flaherty K, Fox BA, Gajewski TF, Gershenwald JE, Gogas H, Grossmann K, Hauschild A, Hodi FS, Kefford R, Kirkwood JM, Leachmann S, Maio M, Marais R, Palmieri G, Morton DL, Ribas A, Stroncek DF, Stewart R, Wang E, Mozzillo N, Marincola FM. Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med 2012;10:83. [PMID: 22551296 DOI: 10.1186/1479-5876-10-83] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
98 Mozzillo N, Ascierto P. Reduction of circulating regulatory T cells by intravenous high-dose interferon alfa-2b treatment in melanoma patients. Clin Exp Metastasis 2012;29:801-5. [PMID: 22752507 DOI: 10.1007/s10585-012-9504-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
99 Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. Immunotherapy of cancer in 2012. CA Cancer J Clin 2012;62:309-35. [PMID: 22576456 DOI: 10.3322/caac.20132] [Cited by in Crossref: 255] [Cited by in F6Publishing: 253] [Article Influence: 25.5] [Reference Citation Analysis]
100 Rubin KM, Vona K, Madden K, McGettigan S, Braun IM. Side effects in melanoma patients receiving adjuvant interferon alfa-2b therapy: a nurse's perspective. Support Care Cancer 2012;20:1601-11. [PMID: 22562583 DOI: 10.1007/s00520-012-1473-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
101 Byrne KT, Turk MJ. New perspectives on the role of vitiligo in immune responses to melanoma. Oncotarget 2011;2:684-94. [PMID: 21911918 DOI: 10.18632/oncotarget.323] [Cited by in Crossref: 59] [Cited by in F6Publishing: 64] [Article Influence: 5.9] [Reference Citation Analysis]
102 Okada H, Khoury SJ. Type17 T-cells in central nervous system autoimmunity and tumors. J Clin Immunol 2012;32:802-8. [PMID: 22454247 DOI: 10.1007/s10875-012-9686-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
103 Pulido J, Kottke T, Thompson J, Galivo F, Wongthida P, Diaz RM, Rommelfanger D, Ilett E, Pease L, Pandha H, Harrington K, Selby P, Melcher A, Vile R. Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma. Nat Biotechnol 2012;30:337-43. [PMID: 22426030 DOI: 10.1038/nbt.2157] [Cited by in Crossref: 78] [Cited by in F6Publishing: 74] [Article Influence: 7.8] [Reference Citation Analysis]
104 Orentas RJ, Lee DW, Mackall C. Immunotherapy targets in pediatric cancer. Front Oncol 2012;2:3. [PMID: 22645714 DOI: 10.3389/fonc.2012.00003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 22] [Article Influence: 1.2] [Reference Citation Analysis]
105 Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480-489. [PMID: 22193102 DOI: 10.1038/nature10673] [Cited by in Crossref: 2030] [Cited by in F6Publishing: 2124] [Article Influence: 184.5] [Reference Citation Analysis]
106 Tarhini AA, Cherian J, Moschos SJ, Tawbi HA, Shuai Y, Gooding WE, Sander C, Kirkwood JM. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol. 2012;30:322-328. [PMID: 22184371 DOI: 10.1200/jco.2011.37.5394] [Cited by in Crossref: 102] [Cited by in F6Publishing: 95] [Article Influence: 9.3] [Reference Citation Analysis]
107 Davar D, Tarhini A, Kirkwood JM. Adjuvant therapy: melanoma. J Skin Cancer 2011;2011:274382. [PMID: 22220281 DOI: 10.1155/2011/274382] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
108 Tanese K, Grimm EA, Ekmekcioglu S. The role of melanoma tumor-derived nitric oxide in the tumor inflammatory microenvironment: Its impact on the chemokine expression profile, including suppression of CXCL10. Int J Cancer 2012;131:891-901. [DOI: 10.1002/ijc.26451] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
109 Lee S, Margolin K. Cytokines in cancer immunotherapy. Cancers (Basel) 2011;3:3856-93. [PMID: 24213115 DOI: 10.3390/cancers3043856] [Cited by in Crossref: 329] [Cited by in F6Publishing: 344] [Article Influence: 29.9] [Reference Citation Analysis]
110 Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, Lee H, Arthur CD, White JM, Kalinke U, Murphy KM, Schreiber RD. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 2011;208:1989-2003. [PMID: 21930769 DOI: 10.1084/jem.20101158] [Cited by in Crossref: 585] [Cited by in F6Publishing: 618] [Article Influence: 53.2] [Reference Citation Analysis]
111 Gast A, Bermejo JL, Claus R, Brandt A, Weires M, Weber A, Plass C, Sucker A, Hemminki K, Schadendorf D, Kumar R. Association of inherited variation in Toll-like receptor genes with malignant melanoma susceptibility and survival. PLoS One 2011;6:e24370. [PMID: 21931695 DOI: 10.1371/journal.pone.0024370] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 3.9] [Reference Citation Analysis]
112 Nicholas C, Lesinski GB. Immunomodulatory cytokines as therapeutic agents for melanoma. Immunotherapy 2011;3:673-90. [PMID: 21554095 DOI: 10.2217/imt.11.45] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 4.2] [Reference Citation Analysis]
113 Chang C, Gershwin ME. Drug-induced lupus erythematosus: incidence, management and prevention. Drug Saf 2011;34:357-74. [PMID: 21513360 DOI: 10.2165/11588500-000000000-00000] [Cited by in Crossref: 65] [Cited by in F6Publishing: 53] [Article Influence: 5.9] [Reference Citation Analysis]
114 Li HS, Gelbard A, Martinez GJ, Esashi E, Zhang H, Nguyen-Jackson H, Liu YJ, Overwijk WW, Watowich SS. Cell-intrinsic role for IFN-α-STAT1 signals in regulating murine Peyer patch plasmacytoid dendritic cells and conditioning an inflammatory response. Blood 2011;118:3879-89. [PMID: 21828128 DOI: 10.1182/blood-2011-04-349761] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 3.1] [Reference Citation Analysis]
115 Bacher N, Graulich E, Jonuleit H, Grabbe S, Steinbrink K. Interferon-α abrogates tolerance induction by human tolerogenic dendritic cells. PLoS One 2011;6:e22763. [PMID: 21818385 DOI: 10.1371/journal.pone.0022763] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
116 Chang GY, Kohrt HE, Stuge TB, Schwartz EJ, Weber JS, Lee PP. Cytotoxic T lymphocyte responses against melanocytes and melanoma. J Transl Med 2011;9:122. [PMID: 21794122 DOI: 10.1186/1479-5876-9-122] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
117 Hiura Y, Nakanishi T, Tanioka M, Takubo T, Moriwaki S. Identification of Autoantibodies for α and γ-Enolase in Serum from a Patient with Melanoma. Jpn Clin Med 2011;2:35-41. [PMID: 23885189 DOI: 10.4137/JCM.S6256] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
118 Hauschild A. Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations? Curr Oncol 2009;16:3-6. [PMID: 19526078 DOI: 10.3747/co.v16i3.447] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
119 White RL, Ayers GD, Stell VH, Ding S, Gershenwald JE, Salo JC, Pockaj BA, Essner R, Faries M, Charney KJ. Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database. Ann Surg Oncol. 2011;18:3593-3600. [PMID: 21647761 DOI: 10.1245/s10434-011-1826-9] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 5.8] [Reference Citation Analysis]
120 Guenterberg KD, Lesinski GB, Mundy-Bosse BL, Karpa VI, Jaime-Ramirez AC, Wei L, Carson WE 3rd. Enhanced anti-tumor activity of interferon-alpha in SOCS1-deficient mice is mediated by CD4⁺ and CD8⁺ T cells. Cancer Immunol Immunother 2011;60:1281-8. [PMID: 21604070 DOI: 10.1007/s00262-011-1034-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
121 Aricò E, Castiello L, Urbani F, Rizza P, Panelli MC, Wang E, Marincola FM, Belardelli F. Concomitant detection of IFNα signature and activated monocyte/dendritic cell precursors in the peripheral blood of IFNα-treated subjects at early times after repeated local cytokine treatments. J Transl Med 2011;9:67. [PMID: 21586124 DOI: 10.1186/1479-5876-9-67] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
122 Simons DL, Lee G, Kirkwood JM, Lee PP. Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients. J Transl Med 2011;9:52. [PMID: 21545749 DOI: 10.1186/1479-5876-9-52] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
123 Bouwhuis MG, Gast A, Figl A, Eggermont AM, Hemminki K, Schadendorf D, Kumar R. Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis? Cancer Immunol Immunother 2010;59:303-12. [PMID: 19672595 DOI: 10.1007/s00262-009-0751-2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 2.7] [Reference Citation Analysis]
124 Byrne KT, Côté AL, Zhang P, Steinberg SM, Guo Y, Allie R, Zhang W, Ernstoff MS, Usherwood EJ, Turk MJ. Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma. J Clin Invest 2011;121:1797-809. [PMID: 21540555 DOI: 10.1172/JCI44849] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
125 Santini SM, Lapenta C, Donati S, Spadaro F, Belardelli F, Ferrantini M. Interferon-α-conditioned human monocytes combine a Th1-orienting attitude with the induction of autologous Th17 responses: role of IL-23 and IL-12. PLoS One 2011;6:e17364. [PMID: 21387004 DOI: 10.1371/journal.pone.0017364] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
126 Bouwhuis MG, ten Hagen TL, Eggermont AM. Immunologic functions as prognostic indicators in melanoma. Mol Oncol 2011;5:183-9. [PMID: 21367679 DOI: 10.1016/j.molonc.2011.01.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
127 Krauze MT, Tarhini A, Gogas H, Kirkwood JM. Prognostic significance of autoimmunity during treatment of melanoma with interferon. Semin Immunopathol. 2011;33:385-391. [PMID: 21279809 DOI: 10.1007/s00281-011-0247-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
128 Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist. 2011;16:5-24. [PMID: 21212434 DOI: 10.1634/theoncologist.2010-0190] [Cited by in Crossref: 342] [Cited by in F6Publishing: 329] [Article Influence: 31.1] [Reference Citation Analysis]
129 Alexandrescu DT, Ichim TE, Riordan NH, Marincola FM, Di Nardo A, Kabigting FD, Dasanu CA. Immunotherapy for melanoma: current status and perspectives. J Immunother 2010;33:570-90. [PMID: 20551839 DOI: 10.1097/CJI.0b013e3181e032e8] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 4.7] [Reference Citation Analysis]
130 Heimberger AB, Sampson JH. Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? Neuro Oncol 2011;13:3-13. [PMID: 21149252 DOI: 10.1093/neuonc/noq169] [Cited by in Crossref: 73] [Cited by in F6Publishing: 73] [Article Influence: 6.1] [Reference Citation Analysis]
131 Dessinioti C, Gogas H, Stratigos AJ. Advances and trends in dermato-oncology. Expert Rev Anticancer Ther 2010;10:1691-6. [PMID: 21080796 DOI: 10.1586/era.10.166] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
132 Shah AA, Rosen A, Hummers L, Wigley F, Casciola-Rosen L. Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum 2010;62:2787-95. [PMID: 20506513 DOI: 10.1002/art.27549] [Cited by in Crossref: 140] [Cited by in F6Publishing: 132] [Article Influence: 11.7] [Reference Citation Analysis]
133 Kähler KC, Egberts F, Hauschild A. [Current aspects of adjuvant therapy of malignant melanoma]. Hautarzt 2010;61:523-31; quiz 532-3. [PMID: 20512304 DOI: 10.1007/s00105-010-1964-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
134 Gogas H, Dafni U, Koon H, Spyropoulou-Vlachou M, Metaxas Y, Buchbinder E, Pectasides E, Tsoutsos D, Polyzos A, Stratigos A, Markopoulos C, Panagiotou P, Fountzilas G, Castana O, Skarlos P, Atkins MB, Kirkwood JM. Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial. J Transl Med 2010;8:108. [PMID: 21044351 DOI: 10.1186/1479-5876-8-108] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
135 Cantaert T, Baeten D, Tak PP, van Baarsen LG. Type I IFN and TNFα cross-regulation in immune-mediated inflammatory disease: basic concepts and clinical relevance. Arthritis Res Ther 2010;12:219. [PMID: 21062511 DOI: 10.1186/ar3150] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 4.6] [Reference Citation Analysis]
136 Gogas H, Kirkwood JM, Falk CS, Dafni U, Sondak VK, Tsoutsos D, Stratigos A, Markopoulos C, Pectasides D, Spyropoulou-Vlachou M. Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon. Cancer 2010;116:4326-33. [PMID: 20549830 DOI: 10.1002/cncr.25211] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
137 Correale P, Rotundo MS, Del Vecchio MT, Remondo C, Migali C, Ginanneschi C, Tsang KY, Licchetta A, Mannucci S, Loiacono L. Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J Immunother. 2010;33:435-441. [PMID: 20386463 DOI: 10.1097/cji.0b013e3181d32f01] [Cited by in Crossref: 142] [Cited by in F6Publishing: 147] [Article Influence: 11.8] [Reference Citation Analysis]
138 Ascierto PA, Napolitano M, Celentano E, Simeone E, Gentilcore G, Daponte A, Capone M, Caracò C, Calemma R, Beneduce G, Cerrone M, De Rosa V, Palmieri G, Castello G, Kirkwood JM, Marincola FM, Mozzillo N. Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment. J Transl Med 2010;8:76. [PMID: 20712892 DOI: 10.1186/1479-5876-8-76] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.9] [Reference Citation Analysis]
139 Rausch MP, Irvine KR, Antony PA, Restifo NP, Cresswell P, Hastings KT. GILT accelerates autoimmunity to the melanoma antigen tyrosinase-related protein 1. J Immunol 2010;185:2828-35. [PMID: 20668223 DOI: 10.4049/jimmunol.1000945] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 2.9] [Reference Citation Analysis]
140 Nesslinger NJ, Ng A, Tsang KY, Ferrara T, Schlom J, Gulley JL, Nelson BH. A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients. Clin Cancer Res 2010;16:4046-56. [PMID: 20562209 DOI: 10.1158/1078-0432.CCR-10-0948] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
141 Disis ML. Immune regulation of cancer. J Clin Oncol. 2010;28:4531-4538. [PMID: 20516428 DOI: 10.1200/jco.2009.27.2146] [Cited by in Crossref: 260] [Cited by in F6Publishing: 276] [Article Influence: 21.7] [Reference Citation Analysis]
142 van den Boorn JG, Konijnenberg D, Tjin EP, Picavet DI, Meeuwenoord NJ, Filippov DV, van der Veen JP, Bos JD, Melief CJ, Luiten RM. Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG. PLoS One 2010;5:e10626. [PMID: 20498710 DOI: 10.1371/journal.pone.0010626] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
143 Shimbo T, Tanemura A, Yamazaki T, Tamai K, Katayama I, Kaneda Y. Serum anti-BPAG1 auto-antibody is a novel marker for human melanoma. PLoS One 2010;5:e10566. [PMID: 20479946 DOI: 10.1371/journal.pone.0010566] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
144 Lesinski GB, Zimmerer JM, Kreiner M, Trefry J, Bill MA, Young GS, Becknell B, Carson WE 3rd. Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells. BMC Cancer 2010;10:142. [PMID: 20398276 DOI: 10.1186/1471-2407-10-142] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
145 Rao UN, Lee SJ, Luo W, Mihm MC Jr, Kirkwood JM. Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials. Am J Clin Pathol 2010;133:646-53. [PMID: 20231618 DOI: 10.1309/AJCPTXMEFOVYWDA6] [Cited by in Crossref: 45] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
146 Rao UN, Lee SJ, Luo W, Mihm MC Jr, Kirkwood JM. Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials. Am J Clin Pathol 2010;133:646-53. [PMID: 20231618 DOI: 10.1309/AJCPTXMEFOVYWDA6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
147 Halama N, Zoernig I, Jaeger D. Advanced malignant melanoma: immunologic and multimodal therapeutic strategies. J Oncol 2010;2010:689893. [PMID: 20224761 DOI: 10.1155/2010/689893] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
148 Kong YC, Wei WZ, Tomer Y. Opportunistic autoimmune disorders: from immunotherapy to immune dysregulation. Ann N Y Acad Sci 2010;1183:222-36. [PMID: 20146718 DOI: 10.1111/j.1749-6632.2009.05138.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
149 Prestwich RJ, Errington F, Diaz RM, Pandha HS, Harrington KJ, Melcher AA, Vile RG. The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther. 2009;20:1119-1132. [PMID: 19630549 DOI: 10.1089/hum.2009.135] [Cited by in Crossref: 127] [Cited by in F6Publishing: 129] [Article Influence: 10.6] [Reference Citation Analysis]
150 Tarhini AA, Kirkwood JM. Clinical and immunologic basis of interferon therapy in melanoma. Ann N Y Acad Sci 2009;1182:47-57. [PMID: 20074274 DOI: 10.1111/j.1749-6632.2009.05073.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
151 Donnelly RP, Young HA, Rosenberg AS. An overview of cytokines and cytokine antagonists as therapeutic agents. Ann N Y Acad Sci 2009;1182:1-13. [PMID: 20074270 DOI: 10.1111/j.1749-6632.2009.05382.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
152 Kirkwood JM, Jukic DM, Averbook BJ, Sender LS. Melanoma in pediatric, adolescent, and young adult patients. Semin Oncol 2009;36:419-31. [PMID: 19835737 DOI: 10.1053/j.seminoncol.2009.07.001] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
153 Adamina M, Rosenthal R, Weber WP, Frey DM, Viehl CT, Bolli M, Huegli RW, Jacob AL, Heberer M, Oertli D, Marti W, Spagnoli GC, Zajac P. Intranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanoma. Mol Ther 2010;18:651-9. [PMID: 19935776 DOI: 10.1038/mt.2009.275] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
154 Lin RB, Fan NF, Chen L, Liu J. Chemoimmunotherapy of chemotherapy-refractory metastatic colorectal cancer with gemcitabine plus FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2. Shijie Huaren Xiaohua Zazhi 2009; 17(32): 3346-3350 [DOI: 10.11569/wcjd.v17.i32.3346] [Cited by in CrossRef: 1] [Article Influence: 0.1] [Reference Citation Analysis]
155 Guminski AD, Thompson JF. Predicting response to IL-2 therapy for metastatic melanoma. Expert Rev Anticancer Ther 2009;9:1571-5. [PMID: 19895241 DOI: 10.1586/era.09.131] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
156 Dillon P, Thomas N, Sharpless N, Collichio F. Regression of advanced melanoma upon withdrawal of immunosuppression: case series and literature review. Med Oncol 2010;27:1127-32. [PMID: 19890737 DOI: 10.1007/s12032-009-9348-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
157 Mackensen F, Max R, Becker MD. Interferons and their potential in the treatment of ocular inflammation. Clin Ophthalmol 2009;3:559-66. [PMID: 19898628 DOI: 10.2147/opth.s3308] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
158 Driggers L, Zhang JG, Newcomb EW, Ge L, Hoa N, Jadus MR. Immunotherapy of pediatric brain tumor patients should include an immunoprevention strategy: a medical hypothesis paper. J Neurooncol 2010;97:159-69. [PMID: 19802719 DOI: 10.1007/s11060-009-0016-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
159 Eggermont AM, Testori A, Marsden J, Hersey P, Quirt I, Petrella T, Gogas H, MacKie RM, Hauschild A. Utility of adjuvant systemic therapy in melanoma. Ann Oncol 2009;20 Suppl 6:vi30-4. [PMID: 19617295 DOI: 10.1093/annonc/mdp250] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
160 Gogas H, Eggermont AM, Hauschild A, Hersey P, Mohr P, Schadendorf D, Spatz A, Dummer R. Biomarkers in melanoma. Ann Oncol 2009;20 Suppl 6:vi8-13. [PMID: 19617299 DOI: 10.1093/annonc/mdp251] [Cited by in Crossref: 84] [Cited by in F6Publishing: 82] [Article Influence: 6.5] [Reference Citation Analysis]
161 Kottke T, Pulido J, Thompson J, Sanchez-Perez L, Chong H, Calderwood SK, Selby P, Harrington K, Strome SE, Melcher A, Vile RG. Antitumor immunity can be uncoupled from autoimmunity following heat shock protein 70-mediated inflammatory killing of normal pancreas. Cancer Res 2009;69:7767-74. [PMID: 19738045 DOI: 10.1158/0008-5472.CAN-09-1597] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
162 Bill MA, Bakan C, Benson DM Jr, Fuchs J, Young G, Lesinski GB. Curcumin induces proapoptotic effects against human melanoma cells and modulates the cellular response to immunotherapeutic cytokines. Mol Cancer Ther 2009;8:2726-35. [PMID: 19723881 DOI: 10.1158/1535-7163.MCT-09-0377] [Cited by in Crossref: 64] [Cited by in F6Publishing: 62] [Article Influence: 4.9] [Reference Citation Analysis]
163 Anasagasti-Angulo L, Garcia-Vega Y, Barcelona-Perez S, Lopez-Saura P, Bello-Rivero I. Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study. BMC Cancer 2009;9:262. [PMID: 19643007 DOI: 10.1186/1471-2407-9-262] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
164 Schwaab T, Schwarzer A, Wolf B, Crocenzi TS, Seigne JD, Crosby NA, Cole BF, Fisher JL, Uhlenhake JC, Mellinger D. Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients. Clin Cancer Res. 2009;15:4986-4992. [PMID: 19622576 DOI: 10.1158/1078-0432.CCR-08-3240] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 4.9] [Reference Citation Analysis]
165 Jilaveanu L, Zito C, Lee SJ, Nathanson KL, Camp RL, Rimm DL, Flaherty KT, Kluger HM. Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib. Clin Cancer Res 2009;15:1076-85. [PMID: 19188183 DOI: 10.1158/1078-0432.CCR-08-2280] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
166 Dummer R, Mangana J. Long-term pegylated interferon-alpha and its potential in the treatment of melanoma. Biologics 2009;3:169-82. [PMID: 19707406 DOI: 10.2147/btt.2009.3051] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
167 Hansson J. Adjuvant therapy of cutaneous melanoma -- current status. Acta Oncol 2006;45:369-72. [PMID: 16760171 DOI: 10.1080/02841860600768895] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
168 Vihinen PP, Hilli J, Vuoristo MS, Syrjänen KJ, Kähäri VM, Pyrhönen SO. Serum VEGF-C is associated with metastatic site in patients with malignant melanoma. Acta Oncol 2007;46:678-84. [PMID: 17562445 DOI: 10.1080/02841860600965020] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
169 Sikora AG, Jaffarzad N, Hailemichael Y, Gelbard A, Stonier SW, Schluns KS, Frasca L, Lou Y, Liu C, Andersson HA, Hwu P, Overwijk WW. IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity. J Immunol 2009;182:7398-407. [PMID: 19494262 DOI: 10.4049/jimmunol.0802982] [Cited by in Crossref: 81] [Cited by in F6Publishing: 78] [Article Influence: 6.2] [Reference Citation Analysis]
170 Tahara H, Sato M, Thurin M, Wang E, Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Wigginton JM, Ambs S, Akutsu Y, Chaussabel D, Doki Y, Eremin O, Fridman WH, Hirohashi Y, Imai K, Jacobson J, Jinushi M, Kanamoto A, Kashani-Sabet M, Kato K, Kawakami Y, Kirkwood JM, Kleen TO, Lehmann PV, Liotta L, Lotze MT, Maio M, Malyguine A, Masucci G, Matsubara H, Mayrand-Chung S, Nakamura K, Nishikawa H, Palucka AK, Petricoin EF, Pos Z, Ribas A, Rivoltini L, Sato N, Shiku H, Slingluff CL, Streicher H, Stroncek DF, Takeuchi H, Toyota M, Wada H, Wu X, Wulfkuhle J, Yaguchi T, Zeskind B, Zhao Y, Zocca MB, Marincola FM. Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med 2009;7:45. [PMID: 19534815 DOI: 10.1186/1479-5876-7-45] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
171 Jacob JB, Kong YC, Nalbantoglu I, Snower DP, Wei WZ. Tumor regression following DNA vaccination and regulatory T cell depletion in neu transgenic mice leads to an increased risk for autoimmunity. J Immunol 2009;182:5873-81. [PMID: 19380836 DOI: 10.4049/jimmunol.0804074] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
172 Yeh S, Karne NK, Kerkar SP, Heller CK, Palmer DC, Johnson LA, Li Z, Bishop RJ, Wong WT, Sherry RM, Yang JC, Dudley ME, Restifo NP, Rosenberg SA, Nussenblatt RB. Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology 2009;116:981-989.e1. [PMID: 19410956 DOI: 10.1016/j.ophtha.2008.12.004] [Cited by in Crossref: 67] [Cited by in F6Publishing: 58] [Article Influence: 5.2] [Reference Citation Analysis]
173 Tsianakas A, Schiller M, Luger TA, Sunderkoetter C. Adjuvant interferon therapy and rheumatoid arthritis--a contraindication? Acta Oncol 2009;48:468-9. [PMID: 18759142 DOI: 10.1080/02841860802314753] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
174 Jolly EC, Clatworthy MR, Lawrence C, Nathan PD, Farrington K. Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis. NDT Plus 2009;2:300-2. [PMID: 25984021 DOI: 10.1093/ndtplus/sfp048] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
175 Lesinski GB, Benninger K, Kreiner M, Quimper M, Young G, Carson WE 3rd. Bortezomib pre-treatment prolongs interferon-alpha-induced STAT1 phosphorylation in melanoma cells. Cancer Immunol Immunother 2009;58:2031-7. [PMID: 19396596 DOI: 10.1007/s00262-009-0710-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
176 Kirkwood JM, Lee S, Moschos SJ, Albertini MR, Michalak JC, Sander C, Whiteside T, Butterfield LH, Weiner L. Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res 2009;15:1443-51. [PMID: 19228745 DOI: 10.1158/1078-0432.CCR-08-1231] [Cited by in Crossref: 109] [Cited by in F6Publishing: 93] [Article Influence: 8.4] [Reference Citation Analysis]
177 Palma JA, Martín-Algarra S. Chronic inflammatory demyelinating polyneuropathy associated with metastatic malignant melanoma of unknown primary origin. J Neurooncol 2009;94:279-81. [PMID: 19266164 DOI: 10.1007/s11060-009-9848-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
178 Kong YC, Jacob JB, Flynn JC, Elliott BE, Wei WZ. Autoimmune thyroiditis as an indicator of autoimmune sequelae during cancer immunotherapy. Autoimmun Rev 2009;9:28-33. [PMID: 19254781 DOI: 10.1016/j.autrev.2009.02.034] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
179 Zafar GI, Grimm EA, Wei W, Johnson MM, Ellerhorst JA. Genetic deficiency of complement isoforms C4A or C4B predicts improved survival of metastatic renal cell carcinoma. J Urol 2009;181:1028-34; discussion 1034. [PMID: 19150565 DOI: 10.1016/j.juro.2008.11.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
180 Kirkwood JM, Tawbi HA, Tarhini AA, Moschos SJ. Does pegylated interferon alpha-2b confer additional benefit in the adjuvant treatment of high-risk melanoma? Nat Clin Pract Oncol 2009;6:70-1. [PMID: 19092800 DOI: 10.1038/ncponc1297] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
181 Caspi RR. Immunotherapy of autoimmunity and cancer: the penalty for success. Nat Rev Immunol 2008;8:970-6. [PMID: 19008897 DOI: 10.1038/nri2438] [Cited by in Crossref: 120] [Cited by in F6Publishing: 113] [Article Influence: 8.6] [Reference Citation Analysis]
182 Racila E, Link BK, Weng WK, Witzig TE, Ansell S, Maurer MJ, Huang J, Dahle C, Halwani A, Levy R, Weiner GJ. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res 2008;14:6697-703. [PMID: 18927313 DOI: 10.1158/1078-0432.CCR-08-0745] [Cited by in Crossref: 114] [Cited by in F6Publishing: 100] [Article Influence: 8.1] [Reference Citation Analysis]
183 Tarhini AA, Stuckert J, Lee S, Sander C, Kirkwood JM. Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol 2009;27:38-44. [PMID: 19047287 DOI: 10.1200/JCO.2008.17.1777] [Cited by in Crossref: 78] [Cited by in F6Publishing: 66] [Article Influence: 5.6] [Reference Citation Analysis]
184 Ascierto PA, Kirkwood JM. Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med 2008;6:62. [PMID: 18954464 DOI: 10.1186/1479-5876-6-62] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 3.8] [Reference Citation Analysis]
185 Buckwalter MR, Srivastava PK. "It is the antigen(s), stupid" and other lessons from over a decade of vaccitherapy of human cancer. Semin Immunol 2008;20:296-300. [PMID: 18715801 DOI: 10.1016/j.smim.2008.07.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
186 Adalid-Peralta L, Godot V, Colin C, Krzysiek R, Tran T, Poignard P, Venet A, Hosmalin A, Lebon P, Rouzioux C, Chene G, Emilie D; Interprim ANRS 112 Study Group. Stimulation of the primary anti-HIV antibody response by IFN-alpha in patients with acute HIV-1 infection. J Leukoc Biol 2008;83:1060-7. [PMID: 18182457 DOI: 10.1189/jlb.1007675] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
187 Okada H, Lieberman FS, Walter KA, Lunsford LD, Kondziolka DS, Bejjani GK, Hamilton RL, Torres-Trejo A, Kalinski P, Cai Q, Mabold JL, Edington HD, Butterfield LH, Whiteside TL, Potter DM, Schold SC Jr, Pollack IF. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med 2007;5:67. [PMID: 18093335 DOI: 10.1186/1479-5876-5-67] [Cited by in Crossref: 81] [Cited by in F6Publishing: 85] [Article Influence: 5.4] [Reference Citation Analysis]
188 Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, Yellin M, Nichol G, White DE, Steinberg SM, Rosenberg SA. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007;13:6681-6688. [PMID: 17982122 DOI: 10.1158/1078-0432.ccr-07-0187] [Cited by in Crossref: 472] [Cited by in F6Publishing: 458] [Article Influence: 31.5] [Reference Citation Analysis]
189 Critchley-Thorne RJ, Yan N, Nacu S, Weber J, Holmes SP, Lee PP. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med 2007;4:e176. [PMID: 17488182 DOI: 10.1371/journal.pmed.0040176] [Cited by in Crossref: 99] [Cited by in F6Publishing: 95] [Article Influence: 6.6] [Reference Citation Analysis]
190 Yurkovetsky ZR, Kirkwood JM, Edington HD, Marrangoni AM, Velikokhatnaya L, Winans MT, Gorelik E, Lokshin AE. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res 2007;13:2422-8. [PMID: 17438101 DOI: 10.1158/1078-0432.CCR-06-1805] [Cited by in Crossref: 167] [Cited by in F6Publishing: 150] [Article Influence: 11.1] [Reference Citation Analysis]
191 Copier J, Whelan M, Dalgleish A. Biomarkers for the development of cancer vaccines: current status. Mol Diagn Ther 2006;10:337-43. [PMID: 17154650 DOI: 10.1007/BF03256210] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
192 Soultati AS, Dourakis SP, Alexopoulou A, Deutsch M, Archimandritis AJ. Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C. World J Gastroenterol 2007; 13(8): 1292-1294 [PMID: 17451219 DOI: 10.3748/wjg.v13.i8.1292] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
193 Ferretti G, Felici A, Cognetti F. Controversies on autoimmunity and prognosis in cancer. Br J Cancer 2006;95:763; author reply 764-5. [PMID: 16926834 DOI: 10.1038/sj.bjc.6603313] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
194 Enk AH, Becker JC, Schuler G. Immunotherapy of malignant melanoma - Basic principles and novel therapeutic approaches. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2006;4:635-44. [DOI: 10.1111/j.1610-0387.2005.05038.x-i1] [Reference Citation Analysis]
195 Oyarbide-Valencia K, van den Boorn JG, Denman CJ, Li M, Carlson JM, Hernandez C, Nishimura MI, Das PK, Luiten RM, Le Poole IC. Therapeutic implications of autoimmune vitiligo T cells. Autoimmun Rev 2006;5:486-92. [PMID: 16920575 DOI: 10.1016/j.autrev.2006.03.012] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 4.1] [Reference Citation Analysis]